GET DAILY SIGNALSQuantum BioPharma (QNTM) Q3 2026 Earnings: Watching Cash Burn and Lucid-MS Updates
Key Takeaways
- Quantum BioPharma (QNTM) is expected to report its third-quarter 2026 results — the quarter ended September 30, 2026 — in mid-November, before the market opens.
- As a pre-revenue biopharmaceutical company, the quarter will be judged on operating losses, cash burn, and research-and-development (R&D) progress rather than sales.
- Consensus estimates point to a net loss of roughly $0.50 per share for the quarter, with minimal revenue expected given that none of its drug candidates have reached commercialization.
- Investor attention will center on updates for Lucid-MS, the company's lead candidate in Phase 2 testing for multiple sclerosis (MS), a disease affecting the central nervous system.
- QNTM reported a loss of $0.47 per share in the second quarter of 2026, missing consensus, and the stock has fallen sharply over the trailing 12 months.
- Cash runway and the status of the company's residential-property-backed strategic investment portfolio remain key areas of risk.
- For deeper insight into the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages dedicated to QNTM.
- Explore Trending AI Robots to see how automated strategies are navigating the market this earnings season.
Earnings Context and Why It Matters
Quantum BioPharma Ltd., formerly known as FSD Pharma Inc., is a clinical-stage biopharmaceutical company focused on neurodegenerative, inflammatory, and metabolic disorders as well as alcohol misuse. Because the company has not yet generated product revenue, its quarterly earnings serve primarily as a gauge of spending discipline and capital runway. The upcoming report arrives during a period of significant share-price pressure, with the stock down sharply over the past year and trading near the low end of its 52-week range. For investors, the release offers a checkpoint on whether the company can fund its pipeline — particularly the Phase 2 Lucid-MS program — without excessive dilution, and whether management is making measurable clinical and regulatory progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts do not expect meaningful top-line revenue from QNTM, reflecting the company's pre-commercial stage. Consensus forecasts center on a net loss of approximately $0.50 per share for the third quarter of 2026, though available estimates vary. The more important figures will sit below the headline number: R&D expenses, general and administrative costs, and net cash used in operations. In the second quarter of 2026, the company reported a loss of $0.47 per share, missing consensus, and its first-quarter 2026 loss was substantially wider. Historically, QNTM shares have shown pronounced volatility around earnings, with double-digit percentage moves in both directions, so investors should prepare for outsized price swings regardless of the reported figures. From what I see, reviewing AI Trend Prediction Engine outputs can add useful context on volatility expectations here.
Market Reaction and Investor Sentiment
Sentiment heading into the QNTM report is cautious. The stock has declined substantially over the past year, and short interest has climbed as bearish positioning increased. With the company generating no product revenue, the market is watching for signs that cash is being deployed efficiently and that dilution pressures are manageable. The stock has historically reacted sharply around earnings, with past releases triggering double-digit single-day moves. Key risk factors include a wider-than-expected loss, a shrinking cash balance, or any indication that clinical timelines for Lucid-MS are slipping. Conversely, positive updates on enrollment, regulatory progress, or financing could support a rebound in a stock trading near its lows.
Forward Outlook and Key Factors to Monitor
Looking past the upcoming print, investors should monitor how quickly the company is consuming cash relative to its remaining balance. With only a modest cash position and ongoing clinical expenses, the runway to the next financing event is a central question.
The most important catalyst is the Lucid-MS Phase 2 trial for multiple sclerosis. Progress on patient enrollment, data-readout timing, and any communication with the U.S. Food and Drug Administration (FDA) will likely matter more to the stock than the quarterly loss itself.
Additionally, investors should track the performance of the company's strategic investment segment, which generates returns through loans secured by residential property. Changes in that portfolio's value or cash flow can influence overall liquidity.
Finally, watch for any announcements around dilution, including at-the-market offerings or other capital raises, which have the potential to pressure the share price. The balance between clinical progress and financing needs will define the story in the quarters ahead.
AI Tools in My Research Workflow
When preparing for earnings like this, I turn to Tickeron’s AI Screener to filter for similar biotech names and spot any emerging patterns. It’s a useful way to contextualize the data without spending hours on manual research, helping me build a more informed watchlist ahead of reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
QNTM's Indicator enters downward trend
The Aroon Indicator for QNTM entered a downward trend on November 06, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 316 similar instances where the Aroon Indicator formed such a pattern. In 284 of the 316 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
QNTM moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for QNTM crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for QNTM just turned positive on October 30, 2026. Looking at past instances where QNTM's MACD turned positive, the stock continued to rise in 29 of 38 cases over the following month. The odds of a continued upward trend are 76%.
Following a +5.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where QNTM advanced for three days, in 198 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
QNTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.142) is normal, around the industry mean (3.482). P/E Ratio (-0.469) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. QNTM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the production and processing of hydroponic indoor cannabis.
Industry Biotechnology
Advertisement